Prefilled Syringes Recalled
AM2 PAT, Inc., (Angier, NC) has initiated a nationwide recall of one lot of prefilled Heparin Lock Flush Solution USP (5 mL in 12 mL Syringes), Lot # 070926H.
AM2 PAT, Inc., (Angier, NC) has initiated a nationwide recall of one lot of prefilled Heparin Lock Flush Solution USP (5 mL in 12 mL Syringes), Lot # 070926H. The heparin IV flush syringes, used by patients at home to flush and prevent clotting in IV lines and catheters, have been found to be contaminated with Serratia marcescens, which has resulted in patient infections. The Centers for Disease Control and Prevention (CDC) has confirmed growth of S. marcescens from several unopened syringes of this product. This type of bacterial infection could present a serious adverse health consequence that could lead to life-threatening injuries or death.
The Food and Drug Administration (FDA) has advised consumers and user facilities that have these recalled pre-filled syringes to stop using the product immediately. The affected product should be immediately quarantined and returned to its distributor.
The firm has voluntarily recalled the product after confirming bacterial contamination in some end user samples. The product was distributed in Florida, Texas, Illinois, Colorado, and Pennsylvania.
The FDA has reported from its ongoing inspection of AM2 PAT, Inc.’s facility, it appears that the firm is not in compliance with the Quality System regulation and failed to have adequate controls to ensure necessary sterility of its prefilled syringes. The firm is continuing to work with FDA and CDC to monitor this situation and FDA will provide continuing updates.
There are several lawsuits now pending as a result of the contaminated syringes.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
INTERPHEX 2025: Critical Role of Walk-In Chambers in Bio/Pharma Development and Manufacturing
April 3rd 2025Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, sat down with the PharmTech Group at INTERPHEX 2025 to discuss the design and critical role of walk-in chambers in the bio/pharmaceutical industry.
